The utility of copy number variation (CNV) in studies of hypertension-related left ventricular hypertrophy (LVH): rationale, potential and challenges by unknown
BoonPeng and Yusoff Molecular Cytogenetics 2013, 6:8
http://www.molecularcytogenetics.org/content/6/1/8REVIEW Open AccessThe utility of copy number variation (CNV) in
studies of hypertension-related left ventricular
hypertrophy (LVH): rationale, potential and
challenges
Hoh BoonPeng1,2* and Khalid Yusoff2Abstract
The ultimate goal of human genetics is to understand the role of genome variation in elucidating human traits and
diseases. Besides single nucleotide polymorphism (SNP), copy number variation (CNV), defined as gains or losses of
a DNA segment larger than 1 kb, has recently emerged as an important tool in understanding heritable source of
human genomic differences. It has been shown to contribute to genetic susceptibility of various common and
complex diseases. Despite a handful of publications, its role in cardiovascular diseases remains largely unknown.
Here, we deliberate on the currently available technologies for CNV detection. The possible utility and the potential
roles of CNV in exploring the mechanisms of cardiac remodeling in hypertension will also be addressed. Finally, we
discuss the challenges for investigations of CNV in cardiovascular diseases and its possible implications in diagnosis
of hypertension-related left ventricular hypertrophy (LVH).
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Genetic variation in human genome exists in different
forms, ranging from large, cytogenetically visible chromo-
somal alterations to submicroscopic variations including
structural changes involving insertion/deletion of large
DNA segment, segmental duplication, copy number
changes and inversion, to the molecular level of presence/
absence of transposable elements, variable number of tan-
dem repeat (VNTR), and changes of a single base pair
known as single nucleotide polymorphism (SNP).
SNP was thought to be the predominant form of vari-
ation in human genome and accounted for the majority of
phenotypic variability [1]. A number of genome-wide asso-
ciation studies (GWAS) had reported the relation of these
common variants in human disease susceptibility. For in-
stance, the Wellcome Trust Case Control Consortium* Correspondence: hbpeng@salam.uitm.edu.my
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distribution, and reproduction in any medium(WTCCC) involving 17,000 samples, studied seven com-
mon diseases namely, hypertension, Crohn’s disease, type I
diabetes, type II diabetes, coronary heart disease, rheuma-
toid arthritis and bipolar disorder [2]. Many other
GWASes have identified genetic associations of a wide
range of common and complex diseases [eg. 3-7]. To date,
the number of reported GWAS is still growing exponen-
tially (http://www.genome.gov/gwastudies/).
Recently, an alternative form of genetic variation has
gained much interest namely, Copy Number Variation
(CNV). Since the first report [8,9], it has emerged as an im-
portant genetic marker in addition to SNP. It is conceivable
that CNV will be taking its place alongside SNP in various
genetic studies in the near future. Hence it is timely to re-
view the potential role of CNV in understanding complex
polygenic conditions in particular cardiovascular diseases,
including hypertension and its complications. This review
discusses the possible utility of CNV in delineating the
mechanisms of cardiac remodeling in hypertension and its
challenges in translation to clinical practice.d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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CNV is recognized as a form of structural variation, in-
volving changes of copy number of a large segment of
DNA (>1 Kb) composed of duplications, deletions, and
complex multi-site variants introduced by non-allelic
homologous recombination [10,11]. It is by and large the
most prevalent type of structural variation identified to
date [12]. Figure 1 illustrates the types of genomic alter-
ations resulting in the formation of structural variation
and copy number variations in the genome.
Despite technological limitations in CNV discovery,
this genetic marker is estimated to cover ~12 – 15% of
the human genome [13,14]. Interestingly, there is a sig-
nificant relationship between the CNV regions and gene
content - a substantial proportion of CNVs are found at
the gene-enriched regions in particular those “environ-
mental sensitive” genes, which influence the responses
to environmental stimuli [15,16]. Indeed a significant as-
sociation either with gene expression variability [17], or
the important regulatory sequences that are situated far
apart from the actual target gene [12].
Initially, CNV was thought to be pathogenic to rare
genomic disorders [12,18,19]. However, this variability
appears virtually in all “phenotypically normal” individ-
uals reported to date [8,9,20-22]. It has been attributed
to a number of susceptibility of common and complex
diseases [23-28], neuropsychiatric diseases [29-33], and
notably, cardiovascular diseases [34,35].Figure 1 Genomic alterations involving large segments of DNA
resulting in formation of structural variation and copy number
variation.Technology for CNV detection and analysis
CNV can be detected and analyzed by different technolo-
gies, both at the genome-wide scale and the locus specific
level. Details of these technologies have been well de-
scribed [36,37].
At the genome-wide level, the following methods are
predominantly in use currently:
i) array-Comparative Genomic Hybridization (aCGH).
This assay uses an array of probes where
differentially labeled test and reference DNA are
jointly hybridized to the array [36,37]. Detection of
CNV is based on the intensity ratio of the labeled
probes. Two major technologies are available for
aCGH. Agilent Technologies commercializes high-
density arrays, up to 1 million probes; while
NimbleGen Technology produces arrays with 2.1
million probes.
ii) SNP array. Although this assay was originally
developed for investigations of single nucleotide
variation, it is increasingly being used to mine
CNVs, based on the probe intensity information
obtained. In SNP array, no reference DNA is being
labeled. Instead, CNV is identified via comparing
the probe intensities of the test DNA with different
individuals. Two major platforms are available in the
industry. Affymetrix produces high-density “hybrid”
arrays, accommodating 1.8 million of SNP and CNV
probes. Whilst the Illumina produces up to 5
million SNP probes in a single array, the highest
density in the microarray technology thus far.
Whilst SNP array provides both information of SNP
and CNV with a higher density, aCGH has a better
signal accuracy. Another advantage of SNP array/
“hybrid” array over aCGH is its ability to identify
the runs of homozygosity (ROH), providing a more
informative analysis. ROH is defined as a large DNA
segment (typically > 1 Mb) with the presence of
uninterrupted homozygosity resulting from
mutational events such as uniparental disomy
(UPD), hemizygous deletion and loss of
heterozygosity (LOH) [38]. Often it is challenging to
distinguish between the ROH with a copy number
deletion and with the presence of both homozygous
alleles. SNP array has the ability to differentiate the
two types of ROH via inspection of the genotype
calls and probe signal intensity ratio simultaneously.
Several studies on ROH and complex diseases have
been reported recently [39,40].
iii) Fluorescent in situ Hybridization (FISH). This
approach was initially used to detect various
syndromic diseases involving larger scale
chromosomal alternations. It hybridizes
fluorescently labeled probes to the chromosomal
Figure 2 Molecular pathways of left ventricular (LVH)
pathogenesis.
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subsequently visualized under fluorescent
microscopy. However, one major limitation of FISH
in CNV analysis is its low resolution, making it
incapable of accurately detecting any CNV smaller
than 5 Mb [36], thus rendering it inappropriate for
study of common and complex disease like LVH.
At the locus specific level, technologies being utilized in
CNV quantification of a particular candidate gene includ-
ing, but not restricted to, Multiplex Ligation-dependent
Probe Amplification (MLPA), quantitative PCR (qPCR),
and Paralogue Ratio Test (PRT). MLPA utilizes the
principle of multiplex PCR and ligation, simultaneously
detecting CNV in multiple regions in a single reaction,
based on its PCR ligated products. The copy number of
the sample is the measurement of the intensity of the
product relative to control DNA [41]. qPCR is the
commonest and simplest assay for CNV analysis. It mea-
sures the fluorescence signals of the targeted sequence
relative to a reference gene (e.g. FOXP2 and TERT) [41].
PRT uses a single primer pair to amplify precisely two
products, one from the targeted CNV region and the
other from a single copy reference locus [42]. Our experi-
ence suggests that PRT was more accurate in determining
copy number calls compared to other PCR based assays.
The introduction of high throughput next generation
sequencing has significantly increased the resolution and
sensitivity of CNV detection. However, the cost of ex-
periment is considerably higher and may not be afford-
able by most laboratories.
Left Ventricular Hypertrophy (LVH)
LVH is an independent risk factor for the development
of clinical events such as heart failure, cardiac arrhyth-
mias, stroke and cardiovascular mortality [43,44]. A re-
cent report suggested the prevalence of LVH at 36%
globally, based on echocardiographic studies [45]. In
Malaysia, the prevalence of LVH was reported to be 24%
based on echocardiography [46]. Initially it is a physio-
logical response to hemodynamic and/or biomechanical
stress, as in hypertension [47,48]. Later the hypertrophy
is mal-adaptive and counterproductive, and impacts ad-
versely on the prognosis. LVH remains a highly frequent
indicator for cardiac damage among hypertensive pa-
tients [45]. The development of LVH in a patient with
hypertension worsens the prognosis of the patient. This
condition has a complex multifactorial and polygenic
basis for its pathogenesis.
Control of hypertension and reversal of hypertension-
related LVH is possible, resulting in improved progno-
sis. Identification of patients at risk for developing
hypertension-related LVH may lead to early interven-
tions to prevent its development, hence avoiding itssequelae and complications. This may further improve
the prognosis and help increase adherence to treatment
among these patients. Thus early diagnosis and im-
proved understanding on the pathogenesis of LVH may
lead to more effective therapeutic strategies [49].
Genetics of LVH
The molecular and biochemical pathways of LVH
pathogenesis have been well described [43,44,47,50-52].
Briefly, mechanical input on the myocytes is transduced
into biochemical event by initiation of signaling at the
cell membrane. Neurohormonal and endocrine hor-
mones (e.gAng II, EDN I, IGF I) bind to Angiotensin II
type 1 and type 2, β-adrenegic and endothelin receptors
which coupled to heteromeric Gq-proteins, induce
phospholipase C (PLC) and protein kinase C (PKC)
activation and subsequently production of inositol
1,4,5- triphosphate [43,44,50] (Figure 2). Downstream,
the release of Ca2+ triggers the calcineurin-calmodulin
pathways, which activates various transcription factors
including nucleus factor activated T cell (NFAT) and
myocyte enhancer factor 2 (MEF2), JNKs, and GATAs
[44,47,50,52]. The calcineurin pathway is also closely
connected to several ion channel pathways, including
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(NHE) pathways. Activation of NHE pathway results in
increased Na+, thus increasing the Ca2+ influx via NCX
pathway, and initiating cardiac hypertrophy signaling.
At the same time, NFAT transcription factor, which was
triggered by calcineurin, interacts with the ANP/BNP
pathways [43]. Other suggested pathways include, but
not limited to, the PPAR, metalloproteinase (MMP) and
mitogen-activated protein kinase (MAPK). The combin-
ation of these mechanisms conspires to initiate cardiac
hypertrophy. These complex networks interacting with
each other, together with pleiotropic and/or epistasis ef-
fects of the molecular pathways provide a substantial
challenge to the efforts of mapping the causative genes.
LVH can be reversed by specific anti-hypertensive
agents. Losartan, an angiotensin receptor blocker, has
shown clinical benefit of this reversal beyond controlling
the blood pressure [53]. Although a number of candidate
gene association studies suggested the involvement of
Renal Angiotensin System (RAS) in LVH pathogenesis,
this association remains inconclusive, as results were not
consistently replicated [54,55]. Notably, a genome-wide
association study (GWAS) from the HyperGEN Study
showed no significant association of RAS genes with LVH,
instead calcineurin related genes seemed responsible for
the development of LVH [55,56]. However when the same
study cohort (HyperGEN) was tested on candidate genes
ACE and AGT variants, significant association with LV
mass was detected [57]. On top of that, a meta-GWAS
published recently found no significant association signals
of any of the RAS related gene with LV mass and function
[58]; whilst Arnett et al. [59] reported that the NCAM1
was associated with LV wall thickness. Further, Gallego-
Delgado et al. [60] showed that RAS mediated genes were
not up- nor down-regulated in a transcriptomic study.
These findings further strengthen the evidence that the in-
fluence of RAS to LVH is most likely indirect. The mech-
anism of action of Losartan could possibly be explained
thus: it selectively blocks Angiotensin II receptor I (AGTRI)
but allowing continued signaling via Angiotensin II Recep-
tor II (AGTRII) which reduces cellular proliferation, fibrosis
and Matrix Metalloproteinase (MMP) activities by normal-
izing the calcineurin activity and the DNA binding of the
NFAT signaling, yet increases apoptosis in cardiac cells
[61,62]. Collectively, whether a strategy specific to reduce
LVH provides additional clinical advantage or simply to re-
verse the complication by controlling blood pressure is
debatable.
Several observations can be made based on the genetic
studies of LVH:
i) Selection of candidate genes solely based on an
understanding of the biochemical roles of encoded
proteins is not comprehensive thus may lead toinappropriate selection of candidate genes or SNPs.
Therefore, an unbiased approach (often with
multiple hypotheses) such as genome-wide screening
[63] is always recommended to study complex traits
such as hypertension-related LVH. Further,
interactions between genes and environment as well
as haplotype analyses have been insufficient thus
potential biological influence of a particular
candidate gene may have been masked [64].
ii) Precise phenotyping. The first generation of GWAS
completed by the Wellcome Trust Case–control
Consortium (WTCCC) failed to achieve a genome-
wide significant level in hypertension [2] and up to
25% of the population based “controls” were
misclassified [65]. This diluted the statistical effects
thus biased towards null [65,66]. Therefore,
obtaining a “clean” and standardized case and control
group to one particular trait (example in this case,
LV wall thickness, or LV mass) from a particular
homogenous cohort is essential. In order to increase
the power of detection, one should consider deriving
samples from an extreme phenotype distribution
[65], for instance the 10th percentile versus the 90th
percentile of the LV wall thickness measurement
[67,68].
iii)Common traits (eg. blood pressure and LV wall or
LV mass) may be controlled by many genes or loci
(in a single or several pathophysiological pathways),
each accounts a small portion of additive genetic
effects on the phenotype. These common variants do
not contribute to immediate effect to the deleterious
phenotypes, rather to late onset common and
complex diseases [69].
iv)“Missing heritability”. The fact that the “unexplained
reason(s)” of the relatively small fraction of individual
disease risk (modest odd ratio of ~1.1-1.5) suggest
that there are missing puzzles when explaining the
trait heritability [70,71]. Instead, the less common
variants (0.5-5%) or rare variants (<0.5%) with
stronger effect may play an equal role as of common
variants, if not greater. Nonetheless, these variants
are often too rare to be detected by common
molecular tools to prove statistical evidence of
association [69].
v) The influence of other forms of genome variations
such as CNV. The potential of this variability is yet
to be fully explored, therefore its impact on common
diseases such as hypertension-related LVH is largely
unknown. There has been arguments though, that
common CNV is typable by tagSNP, therefore they
contribute limited risk factor to disease susceptibility
[12,72]. However, the complex, segmental duplicated
and the rare de novo CNVs are not counted - at least
not with the current genotyping platform (except for
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do not follow the Mendelian inheritance. In addition,
CNV allelic size is often not “taggable” by these SNPs
[12]. Typical examples are shown in a number of
diseases [23,24,27,30-32,73].
CNV and the susceptibility of hypertension-related LVH
Association between CNV and cardiovascular diseases has
not been widely investigated hence less understood, except
that those reviewed by Pollex and Hegele [74], which
mainly described the monogenic disorders of cardiovascu-
lar diseases, and recently on familial dilated cardiomyop-
athy [34]. While studies on gene copy number of LPA
gene in familial hypercholestrolemia (FH), atherosclerosis
and coronary artery disease [19] were performed, the in-
fluence of CNV in non-familial cardiovascular diseases in
particular hypertension-related LVH has not been widely
reported. It is possible that CNV may be involved in
pathogenesis of LVH via its potential biological effects on
the candidate genes (ie regulating the gene dosage) in the
respective pathways. Essentially, complex diseases like
hypertension and other cardiovascular diseases, together
with additive environmental factors, might be more prone
to a “softer” form of variation such as CNVs, which alters
the gene dosage (or regulations) without disrupting the
functions. We have listed here some of the selected candi-
date genes and their molecular/biochemical pathways
(mainly RAS, calcineurin-calmodulin, MAPK and other
above mentioned related signaling pathways) which are
believed to be involved in the pathogenesis of LVH. They
often overlap with known or common CNV regions. The
search was done through the Database of Genomic Va-
riants (DGV; http://projects.tcag.ca/variation/) (date: 17th
May 2012) (Table 1).
Analysis of the CNV with hypertensive LVH though,
should not limit to only those particular “gene-enriched”
CNVs. Studies have shown that CNVs may have impact
on disease susceptibility through their effects on non-
transcribed domains that regulate gene expression at a
distance [10,16]. On the other hand, the possible influ-
ence of rare or de novo CNV should not be ignored in
particular some of the extreme cases. Typical successful
example is shown in thoracic aortic aneurysms and dis-
sections [34].
Implications of CNV in clinical practice of LVH
CNV has opened up potentials for both clinical cases and
laboratory medicine. Its path may lead to the advance-
ment for laboratory tests, which are used to be time con-
suming, labor intensive, expensive and at times difficult to
interpret the result. Together with echocardiography and
ECG examinations [75,76], CNV and/or SNP based geno-
typing could enrich the information for diagnosis, provid-
ing a more accurate and efficient detection tool, of whichearly intervention may be beneficial to hypertensive
patients at risk of developing LVH. A successful example
is the study reported by Wang et al. [77]. Coupled with
the CNV of LPA gene and the SNP identified, this study
managed to increase the detection rate of Familial
Hypercholestrolemia (FH) up to 86.2%. To the best of our
knowledge, this study has yet to be replicated; but if
successful, this result could be useful to design for FH
diagnosis, and consequently be developed as a biomarker
if functionally validated. The genetic profiles obtained may
be useful to estimate disease risk, eg LVH, for the individ-
ual hypertensive patient.
In essence, large segment CNV alternations often involve
numerous neighboring genes, thus shedding the light on
the understanding of syndromology ie wide spectrum of
variations and inconsistencies of phenotypic features [12].
Hypertension-related LVH, expressing a wide range of phe-
notypes, could be explained via gene mapping with CNV.
Though, the applications of CNV in medical decision-
making should be considered with caution at this present
stage, due to the fact that frequencies of occurrence may
vary in a particular population from another.
Despite hunting for causative variants, the primary value
of genome-wide studies – either SNPs or CNVs mapping –
is to provide an etiological connection between biochemical
pathways and disease, thus providing novel insights into
the disease mechanisms. Consequently, knowledge of the
disease pathways can be translated into strategies for pre-
vention, diagnosis and therapy including drug development,
new treatment and diagnostic approaches. Essentially can-
didate CNVs identified in both genome-wide scale, and
locus specific assays, should be functionally validated and
replicated in an independent cohort. Eventually specific
tests of the particular CNV(s) could be developed in clinical
practice.
Major challenges of CNV in cardiovascular diseases
Investigations of CNV in complex diseases, while tempt-
ing, are still in its developing stage. Several challenges
are noted currently and expected to resolve in the near
future, especially with the availability of the massively
parallel high throughput sequencing:
i) Lack of replication in CNV callings and reference
samples for comparison of results. Multiple
commercial arrays available for CNV detection, each
with different resolutions and analytic algorithms,
bias towards the advantage of its own technology.
This leads to a poor replication when reporting
CNV, and lack of a standardized reference sample set
further complicates the analysis efforts [78].
ii) Limitation of the current array based technology
(copy number calls). Due to limitation of the
chemistry, the array-based platforms only allow
Table 1 Candidate genes and their functions in hypertensive LHV pathogenesis
Gene Gene map locus Gene function
RENAL-ANGIOTENSIN SYSTEM/G-COUPLED PROTEIN RECEPTORS:
ATP6AP2 Xp11.4 Muscular smooth muscle contraction. Renin and prorenin cellular receptor.
May mediate renin-dependent cellular responses by activating ERK1 and
ERK2. By increasing the catalytic efficiency of renin in AGT/
angiotensinogen conversion to angiotensin I, it may also play a role in the
renin-angiotensin system (RAS).
Estrogen receptor signaling:
EGFR 7p11.2 Receptor binding to epidermal growth factor. Required by AngII to
mediate ERK activation thus plays a critical role in the LVH induced by
Ang II.
EGF 4q25 Shedding of heparin-binding EGF by ADAM12, induce hypertrophic
signaling via EGFR activation downstream through small G proteins and
the MAPK pathway.
ADAM12 10q26.2 Involved in skeletal muscle regeneration, specifically at the onset of cell
fusion and macrophage-derived giant cells (MGC) and osteoclast
formation from mononuclear precursors. Plays a centre role in cardiac
hypertrophy by interacting with HB-EGF.
ERBB2 17q21.1 A member of the epidermal growth factor (EGF) receptor family of
receptor tyrosine kinases. Essential in cardiac development. Involved in the
EGFR signaling that drives many cellular responses, including changes in
gene expression, cytoskeletal rearrangement, anti-apoptosis and increased
cell proliferation.
ITGB2 (Beta-integrin) 21q22.3 Involved in cell adhesion as well as cell-surface mediated signalling. Links
the extracellular matrix to the intracelluar cytoskeleton. Stretch sensor.
Deletion of this gene/protein leads to cardiac pathology. Gene expression
profile is upregulated in ERbeta knockout mice with cardiac hypertrophy.
ITGB1BP2 (Melusin) Xq13.1 Integrin interacting protein. Sensor of mechanical stress in cardiac
myocytes. An essential component for the phosphorylation (inactivation)
of GSK3-beta. Deletion of this gene leads to cardiac pathology.
CALCINEURIN-CALMODULIN Ca2+ Signaling:
PPP3CA (calcineurin A-alpha) 4q24 Calcium dependent, calmodulin stimulated protein phosphatase.Ca2
+/calmodulin binding.
CALM1 (calmodulin 1) 14q32.11 Mediates the control of large number of enzymes and other proteins by
Ca2+. Involved in a genetic pathway that regulates the centrosome cycle
and progression via cytokinesis.
CALM3 (calmodulin 3) 19q13.2 Together with CALM1 and CALM2, these calmodulin genes give rise to
five transcripts that are present in most tissues. This gene may be
specifically and differently regulated during cardiac cell proliferation and/
or hypertrophy.
CAMK2B (calmodulin kinase) 7p14.3 Calmodulin/Ca2+ signaling. At basal Ca2+ levels, CaMKs are maintained in
a dormant state through autoinhibition. Increase in Ca2+ levels allows
calmodulin to relieve this autoinhibition and activate the kinase activity.
Ion channel pathway: Sodium-Calcium exchange pathway
SLC8A1 (NCX1) 2p22.1
SLC9A2 (NHE) 2q12.1 Sodium-Hydrogen exchange pathway
KCNB2 8q13.3 Regulate the smooth muscle contraction by controlling the influx of Ca2+
through voltage-gated Ca2+ channels
NFAT SIGNALING & OTHERS TRANSCRIPTION FACTORS:
NFATC3 16q22.1 Required in muscle cell, and heart development, as well as smooth
muscle differentiation. Rapid nuclear exit of NFATC is thought to be
onemechanism by which cells distinguish between sustained and
transient calcium signals.
ILF3 19p13.2 Involved in the NFAT transcription signaling. A subunit of the nuclear
factor of activated T-cells (NFAT).
ITPR3@ IPR3 6p21.31 Inositol 1,4,5-triphosphate receptor type 3. Involved in mediating the
release of intracellular calcium.
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Table 1 Candidate genes and their functions in hypertensive LHV pathogenesis (Continued)
GATA4 8p23.1 Transcription factors that regulate genes critical for myocardial
differentiation and function, regulates hypertrophic gene expression.
MCIP-1 (RCAN1) 21q22.12 Modulatory calcineurin interacting protein. Serves as calcineurin–
regulatory protein that inhibit calcineurin when over expressed.
MEF2A 15q26.3 Transcription factor of cardiac hypertrophy cascade. Involved in the
activation of numerous growth factor- and stress-induced genes. Mediates
cellular functions in skeletal and cardiac muscle development.
MAPK3 16p11.2 Act as a signaling cascade that regulates various cellular processes
including proliferation, differentiation and cell cycle progression in
response to a variety of extracellular signals.
JAK2 9p24.1 Involved in a specific subset of cytokine receptor signaling pathways.
Uponreceptor activation JAKs phosphorylate the transcription factors
known as STATs and initiate the JAK-STATsignaling pathway.
CTNNB1 (Beta-catenin) 3p22.1 Cadherin-associated protein. Part of a complex of proteins that constitute
adherens junctions. Involved in the regulation of cell adhesion.
Predominantly localized to the cell membrane, and is part of E-cadherin
/catenin adhesion complexes which are believed to couple cadherins to
the actin cytoskeleton. Structural changes of the extracellular matrix in
LVH are significantly modulated by B-catenin associated signaling
pathways.
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– 4). Thus, analysis of multiple or complex CNV has
always been a challenge.
In view of the above mentioned difficulties, CNV is
usually called by three algorithms, and the consensus of
at least two is defined as “stringent” CNV call [36]. In
addition, validation approaches with other techniques
are always recommended to confirm the CNV detected,
for instance, qPCR, MLPA, paralogue ratio test (PRT),
CGH and FISH (for large CNVs) [13,79,80].
iii) Identification of precise breakpoint is a common
issue of CNV study. Often, the non-identical, but
overlapping copy number alleles is being assigned
into one category, or being misinterpreted as the
same allele. This will definitely affect tests of
association between variation and disease, as
different breakpoints may result in different
biological consequences. DNA sequencing of the
region of interest may resolve this problem.
However, it is laborious in Sanger sequencing for
such purpose [81]; the cost for next-generation
sequencing is expected to be lower in the future
though.
iv) Careful interpretation of the complex CNV data in
both research and medical decision-making is
essential especially when dealing with complex
diseases. How CNV results are applied to research
or medical decision-making needs to be considered
according to the circumstances where it is observed
especially with the awareness of interactions
between single nucleotide alterations and CNVs
[12]. Unexplained familial disorders should berevised with the consideration of the presence of
above mentioned potential technical limitations.
Potential challenge between genomic observation
and clinical implication could be raised when
complex conditions like cardiovascular diseases
require a shift of mindset to approaches like rare
CNVs.
v) The need for an established database, both for
“healthy” populations (such as Database for
Genomic Variants, DGV), or disease cohort (such as
DECIPHER) will be essential, cataloging the
information of genic content of the variant segment
[12,82]. This would help to narrow down the disease
diagnosis by excluding those non-pathogenic, and
focus on the disease-based CNVs.
vi) Cost consideration versus selection of technology.
Effective running cost and ease of assay typing have
always been the major hindrance for clinicians in
CNV analysis. Although the cost for an array-based
global CNV screening has dropped, it is
unaffordable by most patients especially those from
the lower income community. Although locus
specific CNV genotyping assays are more cost
effective, lower resolution and limited information
obtained (as discussed in the earlier section) from
such assays is a drawback. Therefore, comprehensive
CNV mapping and identification of pathogenic
CNV in LVH is needed to ensure that the findings
be translated into clinical practice in the most cost
effective manner.
Conclusion
Molecular cardiological research with CNV provides ample
possibilities for the development of more cardiac-specific
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to the pathology and genetic make-up of the individual pa-
tient. The application of CNV in complex diseases will con-
tinue to grow while array based technology will remain as
the mainstay in the next future. Ongoing development of
technological and sophisticated statistical tools in CNV ana-
lysis should warrant the extensive investigation of the gen-
etics of LVH. However, the growth of this research area is
still in its infancy stage and far from translating into me-
dical implication, thus efficacy of such an approach should
be carefully interpreted.
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